Latest News

STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition

When Gilead Sciences announced its $21 billion acquisition of Immunomedics one week ago, Gilead executives said that clinical data on Immunomedics’ cancer drug Trodelvy — shared confidentially during negotiations — justified the high cost of the deal.

On Saturday, data from Trodelvy studies in bladder cancer and triple-negative breast cancer were presented publicly for the first time at the annual meeting of the European Society for Medical Oncology.

Continue to STAT Plus to read the full story…

Source link

Related posts

Opinion: My life depends on medicine made from plasma. The plasma shortage worries me


Medical News Today: Common food additive may impact gut bacteria, increase anxiety


Medical News Today: Your furniture may contain harmful chemicals


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World